322 related articles for article (PubMed ID: 29286576)
21. Ten-year experience with peritoneal mesothelioma.
Kyziridis D; Hristakis C; Kalakonas A; Vaikos D; Pallas N; Karamveri C; Kyriakopoulos V; Tentes AA
J BUON; 2019; 24(1):391-396. PubMed ID: 30941996
[TBL] [Abstract][Full Text] [Related]
22. Anesthesia and Pain Management for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors in Children, Adolescents, and Young Adults.
Anghelescu DL; Brown CL; Murphy AJ; Davidoff AM; Dickson PV; Glazer ES; Stiles ZE; Bishop MW; Douthitt L; Deneve JL
Ann Surg Oncol; 2019 Jan; 26(1):131-138. PubMed ID: 30353396
[TBL] [Abstract][Full Text] [Related]
23. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
[TBL] [Abstract][Full Text] [Related]
24. Well-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry.
Vogin G; Hettal L; Vignaud JM; Dartigues P; Goere D; Ferron G; Heyd B; Bereder JM; Tuech JJ; Glehen O; de Chaisemartin C; Lherm Y; Villeneuve L; Kepenekian V; Marchal F;
Ann Surg Oncol; 2019 Mar; 26(3):852-860. PubMed ID: 30635798
[TBL] [Abstract][Full Text] [Related]
25. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
[TBL] [Abstract][Full Text] [Related]
26. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
27. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Sugarbaker PH; Chang D
Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
[TBL] [Abstract][Full Text] [Related]
28. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
[TBL] [Abstract][Full Text] [Related]
29. Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study.
Madsen AH; Ladekarl M; Villadsen GE; Grønbæk H; Sørensen MM; Stribolt K; Verwaal VJ; Iversen LH
Ann Surg Oncol; 2018 Feb; 25(2):422-430. PubMed ID: 29214450
[TBL] [Abstract][Full Text] [Related]
30. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
[TBL] [Abstract][Full Text] [Related]
31. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study.
Kotha NV; Baumgartner JM; Veerapong J; Cloyd JM; Ahmed A; Grotz TE; Leiting JL; Fournier K; Lee AJ; Dineen SP; Dessureault S; Clarke C; Mogal H; Zaidi MY; Russell MC; Patel SH; Sussman JJ; Dhar V; Lambert LA; Hendrix RJ; Abbott DE; Pokrzywa C; Lafaro K; Lee B; Greer JB; Fackche N; Lowy AM; Kelly KJ
Ann Surg Oncol; 2019 Jul; 26(7):2234-2240. PubMed ID: 31016486
[TBL] [Abstract][Full Text] [Related]
32. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
33. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
35. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
36. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
37. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
Wong JF; Tan GH; Wang W; Soo KC; Teo MC
World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
[TBL] [Abstract][Full Text] [Related]
38. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis].
Habbel VSA; Mahler EA; Feyerabend B; Oldhafer KJ; Lipp MJ
Z Gastroenterol; 2020 Feb; 58(2):146-151. PubMed ID: 32050285
[TBL] [Abstract][Full Text] [Related]
39. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma.
Tan GH; Cheung M; Chanyaputhipong J; Soo KC; Teo MC
Ann Acad Med Singap; 2013 Jun; 42(6):291-6. PubMed ID: 23842770
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis.
Salti GI; Ailabouni L; Undevia S
Ann Surg Oncol; 2012 May; 19(5):1410-5. PubMed ID: 22302269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]